Skip to main content
      RT @DrMiniDey: How can we better identify patients with #RA-ILD using #EHRs?

      Abs#0561: previously validated algorithms

      Mrinalini Dey DrMiniDey

      4 years ago
      How can we better identify patients with #RA-ILD using #EHRs? Abs#0561: previously validated algorithms have clinical & research utility when applied to EHRs, esp when well-integrated with key info such as CT chest reports #ACR21 @RheumNow https://t.co/OU8BdwqHpc
      RT @drdavidliew: ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs.

      What about in real-wor

      David Liew drdavidliew

      4 years ago
      ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs. What about in real-world data? Looking at CorEvitas, less so LDA: aOR 0.99 MCID in CDAI: 1.06 Even without MTX, both great drug classes for RA Equally so? #ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV
      RT @ericdeinmd: #ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes
      ▶️ 76 osteoporo

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes ▶️ 76 osteoporotic fxs in RA pts, FRAX predicted 67 fx (SIR 1.13, not signif) ▶️ 21 observed hip fx, FRAX predicted 23.3 (SIR 0.9) ⭐️ No differences by ages/sex https://t.co/vWy7EmseZp @Rheumnow https://t.co/8BlzgQYqaV
      RT @doctorRBC: 6 year f/up study of sacroilitis in nr-AxSpA pts
      ⭐️~10% of pts progressed from nr-AxSpa to AS every 2

      Robert B Chao, MD doctorRBC

      4 years ago
      6 year f/up study of sacroilitis in nr-AxSpA pts ⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years Abs#907 #ACR21 @RheumNow https://t.co/kiWGmKhpWu
      RT @DrMiniDey: Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this?
      👉PROMs &

      Mrinalini Dey DrMiniDey

      4 years ago
      Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this? 👉PROMs & treatment response determine long-term SE 👉This may help identify pts benefitting most from interventions to improve SE Abs#0795 #ACR21 @RheumNow https://t.co/dx28WgxNsE https://t.co/7uN6XctnQb
      RT @ericdeinmd: #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
      ▶️No significant correlation b

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
      RT @drdavidliew: In Australia, there's free choice of originator vs biosimilar for etanercept.

      Real-world data shows ex

      David Liew drdavidliew

      4 years ago
      In Australia, there's free choice of originator vs biosimilar for etanercept. Real-world data shows exactly what you'd expect over >48 months - and sometimes it's what you expect that's exactly what you want to see... OPAL data #ACR21 0840 @RheumNow https://t.co/YJA2Cua9cw
      RT @DrMiniDey: It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focu

      Mrinalini Dey DrMiniDey

      4 years ago
      It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focus on abstract #1924, to be presented at the #Epidemiology & #PublicHealth abstract session on Tuesday #ACR21: https://t.co/qHws6B3fFf Watch @RheumNow: https://t.co/OKM7WxIEpR
      ×